Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Martha E, Brown"'
Autor:
Costanza Paoletti, Meredith M. Regan, Samuel M. Niman, Emily M. Dolce, Elizabeth P. Darga, Minetta C. Liu, P. Kelly Marcom, Lowell L. Hart, John W. Smith, Karen L. Tedesco, Eitan Amir, Ian E. Krop, Angela M. DeMichele, Pamela J. Goodwin, Margaret Block, Kimberly Aung, Martha E. Brown, Robert T. McCormack, Daniel F. Hayes
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021)
Abstract Circulating tumor cells (CTC) are prognostic in metastatic breast cancer (MBC). The CTC-endocrine therapy index (CTC-ETI), consisting of CTC-ER (estrogen receptor), BCL2, human epidermal growth factor receptor (HER2), and Ki67 expression, mi
Externí odkaz:
https://doaj.org/article/a4591a6d3a9d4069a97a9133183bb04c
Autor:
Elizabeth P. Darga, Emily M. Dolce, Fang Fang, Kelley M. Kidwell, Christina L. Gersch, Steven Kregel, Dafydd G. Thomas, Anoop Gill, Martha E. Brown, Steven Gross, Mark Connelly, Michael Holinstat, Erin F. Cobain, James M. Rae, Daniel F. Hayes, Costanza Paoletti
Publikováno v:
PLoS ONE, Vol 16, Iss 11 (2021)
Background Immune checkpoint inhibition is effective in several cancers. Expression of programmed death-ligand 1 (PD-L1) on circulating tumor or immune effector cells could provide insights into selection of patients for immune checkpoint inhibition.
Externí odkaz:
https://doaj.org/article/63089b9215d1428799266b1d9644f894
Autor:
Costanza Paoletti, Jose M. Larios, Maria C. Muñiz, Kimberly Aung, Emily M. Cannell, Elizabeth P. Darga, Kelley M. Kidwell, Dafydd G. Thomas, Nahomi Tokudome, Martha E. Brown, Mark C. Connelly, David A. Chianese, Anne F. Schott, N. Lynn Henry, James M. Rae, Daniel F. Hayes
Publikováno v:
Molecular Oncology, Vol 10, Iss 7, Pp 1078-1085 (2016)
Fulvestrant is a dose dependent selective estrogen receptor (ER) down‐regulator (SERD) used in ER‐positive metastatic breast cancer (MBC). Nearly all patients develop resistance. We performed molecular analysis of circulating tumor cells (CTC) to
Externí odkaz:
https://doaj.org/article/7957be4d2fea493c9246bb9e97afb0c8
Autor:
Daniel F. Hayes, David A. Chianese, Mark C. Connelly, James M. Rae, N. Lynn Henry, Anne F. Schott, Dorothy L. Blossom, M. Craig Miller, Kimberly Aung, Martha E. Brown, Nahomi Tokudome, Kelley M. Kidwell, Kent A. Griffith, Dafydd G. Thomas, Maria C. Muñiz, Costanza Paoletti
Background: Endocrine therapy (ET) fails to induce a response in one half of patients with hormone receptor (HR)–positive metastatic breast cancer (MBC), and almost all will eventually become refractory to ET. Circulating tumor cells (CTC) are asso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1aadf3ff396caa8046785d07ed87e779
https://doi.org/10.1158/1078-0432.c.6524091.v1
https://doi.org/10.1158/1078-0432.c.6524091.v1
Autor:
Daniel F. Hayes, David A. Chianese, Mark C. Connelly, James M. Rae, N. Lynn Henry, Anne F. Schott, Dorothy L. Blossom, M. Craig Miller, Kimberly Aung, Martha E. Brown, Nahomi Tokudome, Kelley M. Kidwell, Kent A. Griffith, Dafydd G. Thomas, Maria C. Muñiz, Costanza Paoletti
Table S1. Antibodies used for CTC and tissue studies. Table S2. Stage 2 stopping rules for the cumulative number of successfully assayed patients. Table S3. A. CTC-Enumeration Points based on CTC Enumeration B. CTC-Bio-Pointsa Footnotes:aOnly aliquot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c0a31083669e29babf1577e42bdba37
https://doi.org/10.1158/1078-0432.22458948
https://doi.org/10.1158/1078-0432.22458948
Autor:
Daniel F. Hayes, Andres Forero-Torres, Antonio C. Wolff, Catherine H. Van Poznak, Christos Vaklavas, Tiffany A. Traina, Anna M. Storniolo, Julie R. Nangia, Rita Nanda, Minetta C. Liu, Nancy U. Lin, William J. Irvin, Vandana G. Abramson, Martha E. Brown, Dafydd G. Thomas, Kimberly Aung, Kelley M. Kidwell, Maria C. Muñiz, Yufeng Li, Costanza Paoletti
Purpose: Circulating tumor cells (CTC) are prognostic in metastatic breast cancer (MBC). We tested whether EpCAM-based capture system (CellSearch) is effective in patients with triple-negative (TN) MBC, and whether CTC apoptosis and clustering enhanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc82a93b4e8341969db7d17885cb8b88
https://doi.org/10.1158/1078-0432.c.6524666
https://doi.org/10.1158/1078-0432.c.6524666
Autor:
Daniel F. Hayes, Andres Forero-Torres, Antonio C. Wolff, Catherine H. Van Poznak, Christos Vaklavas, Tiffany A. Traina, Anna M. Storniolo, Julie R. Nangia, Rita Nanda, Minetta C. Liu, Nancy U. Lin, William J. Irvin, Vandana G. Abramson, Martha E. Brown, Dafydd G. Thomas, Kimberly Aung, Kelley M. Kidwell, Maria C. Muñiz, Yufeng Li, Costanza Paoletti
Supplementary Figure 1-5. Supplementary Figure 1. Example of cluster image using the CellSearch® system. Supplementary Figure 2. REMARK diagram of the 19 patients who had elevated CTC (Group B/C) at baseline that were used to study "CTC-response". S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97e12e73b7c8b510c104658757ec14d6
https://doi.org/10.1158/1078-0432.22460996
https://doi.org/10.1158/1078-0432.22460996
Autor:
Daniel F. Hayes, David A. Chianese, Mark C. Connelly, James M. Rae, N. Lynn Henry, Anne F. Schott, Dorothy L. Blossom, M. Craig Miller, Kimberly Aung, Martha E. Brown, Nahomi Tokudome, Kelley M. Kidwell, Kent A. Griffith, Dafydd G. Thomas, Maria C. Muñiz, Costanza Paoletti
Supplementary Figures. Figure S1. Clinical trial study design. Figure S2. Examples of biomarker staining of cultured human breast cancer cell lines after spike and capture from normal human blood using the CellSearch® system. A semi-quantitative sca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86aca4842a09901df75920f502fd5061
https://doi.org/10.1158/1078-0432.22458951
https://doi.org/10.1158/1078-0432.22458951
Autor:
Daniel F. Hayes, Andres Forero-Torres, Antonio C. Wolff, Catherine H. Van Poznak, Christos Vaklavas, Tiffany A. Traina, Anna M. Storniolo, Julie R. Nangia, Rita Nanda, Minetta C. Liu, Nancy U. Lin, William J. Irvin, Vandana G. Abramson, Martha E. Brown, Dafydd G. Thomas, Kimberly Aung, Kelley M. Kidwell, Maria C. Muñiz, Yufeng Li, Costanza Paoletti
Supplementary Table 1. Table illustrating the criteria with which a cell was considered viable, or apoptotic either due to positive M-30 staining and/or visual evidence of apoptosis (nucleic condensat). Legend: Y= Yes, N= No
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4884d6463a9ce0c930f2de55666704a5
https://doi.org/10.1158/1078-0432.22460993
https://doi.org/10.1158/1078-0432.22460993
Autor:
Seock-Ah Im, Jackie Pierce, Kevin Hu, Gayle Marshall, Chia Jen Liu, Manish R. Patel, Scott A. Tomlins, TH Carr, Danielle Carroll, Komal Jhaveri, Daniel F. Hayes, Costanza Paoletti, Richard D. Baird, Justin P.O. Lindemann, Andi K. Cani, Anne C Armstrong, Gaia Schiavon, Aaron M. Udager, J.C. Barrett, Emily M. Dolce, Elizabeth P. Darga, Erika Hamilton, Kimberly Aung, Martha E. Brown, Kieran Bradbury, Teresa Klinowska, Vicky Rowlands, Caroline Dive, Elizabeth A. Harrington
Purpose: The vast majority of advanced ER POS breast cancers eventually cease responding to endocrine (ET) and other therapies leading to evolution of lethal disease. However, timely monitoring of the molecular events associated with response/progres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7ce778bda093ecc2d1fb9ffe222d2c2
https://www.repository.cam.ac.uk/handle/1810/349666
https://www.repository.cam.ac.uk/handle/1810/349666